Tricida Stock Forecast, Price & News

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 74.0% and is now trading at $7.30.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tricida or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Tricida a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tricida wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Tricida.

Tricida, Inc. (NASDAQ:TCDA) issued its quarterly earnings data on Monday, November, 9th. The company reported ($1.55) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.22) by $0.33.
View Tricida's earnings history.

4 brokers have issued 1 year price targets for Tricida's shares. Their forecasts range from $8.00 to $40.00. On average, they anticipate Tricida's stock price to reach $19.50 in the next year. This suggests a possible upside of 167.1% from the stock's current price.
View analysts' price targets for Tricida.

Tricida saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,380,000 shares, an increase of 25.9% from the October 31st total of 3,480,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is presently 3.7 days. Approximately 11.2% of the shares of the stock are sold short.
View Tricida's Short Interest.

Some companies that are related to Tricida include Ligand Pharmaceuticals (LGND), Rhythm Pharmaceuticals (RYTM), MacroGenics (MGNX), Athenex (ATNX), Ocular Therapeutix (OCUL), Phathom Pharmaceuticals (PHAT), Intercept Pharmaceuticals (ICPT), Constellation Pharmaceuticals (CNST), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Zogenix (ZGNX), Cytokinetics (CYTK), Amneal Pharmaceuticals (AMRX), Arcutis Biotherapeutics (ARQT) and Travere Therapeutics (RTRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.90%), JPMorgan Chase & Co. (2.74%), Point72 Asset Management L.P. (2.41%), Federated Hermes Inc. (2.19%), State Street Corp (1.08%) and Massachusetts Financial Services Co. MA (0.74%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl.
View institutional ownership trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., State Street Corp, TD Asset Management Inc., SG Americas Securities LLC, Aigen Investment Management LP, Massachusetts Financial Services Co. MA, and California Public Employees Retirement System. Company insiders that have sold Tricida company stock in the last year include Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Sandra I Coufal, and Wilhelm Stahl.
View insider buying and selling activity for Tricida.

TCDA stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Point72 Asset Management L.P., Voloridge Investment Management LLC, Aperio Group LLC, Engineers Gate Manager LP, Squarepoint Ops LLC, Berman Capital Advisors LLC, and ExodusPoint Capital Management LP. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc.
View insider buying and selling activity for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $7.30.

Tricida has a market capitalization of $366.35 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 157 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]